Review Article
Lipoplatin Treatment in Lung and Breast Cancer
Table 2
phase III studies with lipoplatin.
| | Author | Chemotherapeutic schema | Study phase | Diseases | Pts N° | Line | OR% | SD% | mTTP | mOS |
| | Komas et al. [11] and Stathopoubs et al. [12] | Lipoplatin 120 mg/m2 on days 1, 8, and 15 plus gemcitabine 1 g/m2 on days 1 and 8 in a 21-day cycle | Phase III | NSCLC | 33 | 1st line | 25% | 23% | | |
| | cisplatin 100 mg/m2 on day 1 plus gemcitabine 1 g/m2 on days 1 and 8 in a 21-day cycle | | | 26 | | 25% | 12% | | | | Boulikas et al. [13] | 100 mg/m2/d Lipoplatin as a 4 h i.v. infusion (days 1, 8, 15) plus 1000 mg/m2/d 5-FU (days 1–5 continuous infusion) every 21 days | Phase III | SCCHN | 25 | | 19% | 64% | | |
| | 100 mg/ (m2 day) cisplatin with prehydration and posthydration (day 1) plus / 1000 mg/m2/d / 5-FU (days 1–5 continuous infusion) every 21 days | 21 | | 38.8% | 50% | | |
| | Stathopoulos et al. [14] | Lipoplatin 200 mg/m2 plus 135 mg/m2 paclitaxel administered on day 1 repeated every 2 weeks | Phase III | | 114 (79) | 1st line | 59.70% (59.9%) | 36.8% | 6.5 (10) m | 9 m | | Cisplatin 75 mg/m2 135 mg/m2 paclitaxel, administered every 2 weeks | | NSCLC (adenocarcinoma and undifferentiated NSCLC) | 115 (73) | | 47.00% (42.5%) | 43.5% | 6 (8) m | 10 m |
|
|
